講演情報
[S15-5]Clinical cancer genomics and liquid biopsy for pediatric malignancy
○加藤 元博 (東京大学 医学部 小児科)
Cancer is a disease caused by the accumulation of genomic alteration which leads to the growth/survival advantage of abnormal cells. The genomic profile of cancer cells is closely associated with its clinical phenotype, and multigene testing is implemented as clinical cancer genomics. For pediatric cancer, genomic profiling tests are used not only for therapeutic targets but also for diagnostic classifications and prognostic prediction. In addition, germline findings are also important in understanding the molecular pathogenesis of pediatric malignancy, due to a high prevalence of germline variants in cancer-predisposing genes. On another note, recent advances in technology enabled us to detect small amounts of DNA derived from solid tumors in peripheral blood. This “liquid biopsy” is suitable for pediatric cancer, because of the rapid progression of cancer cells. For children, liquid biopsy can be used not only for qualitative detection but also for quantitative assessment.
In this symposium, we will provide updated information on clinical cancer genomics and liquid biopsy for pediatric cancer, and will present an outline of our a prospective clinical trial “JCCG-TOP2”, which has been conducted to establish a platform for performing multigene testing.
In this symposium, we will provide updated information on clinical cancer genomics and liquid biopsy for pediatric cancer, and will present an outline of our a prospective clinical trial “JCCG-TOP2”, which has been conducted to establish a platform for performing multigene testing.